MALDI mass spectrometry | GenomeWeb

MALDI mass spectrometry

Certain alleles at two SNP sites in TP53 coincided with decreased colorectal cancer risk or an earlier time of disease onset in a study of almost 300 Taiwanese individuals with Lynch syndrome.

Unlike MALDI-based microbial ID efforts from companies like Bruker and BioMérieux, the SimulTOF effort is focused not on clinical work but rather research uses.

Conference attendees discussed the growing number of MALDI-TOF applications while recognizing that LDT regulation poses a particular threat to mass spec-based tests.

NEW YORK (GenomeWeb News) – The National Cancer Institute has awarded Labcyte $1 million to create a process for detecting cancer-associated proteins in samples, the company announced today.

NEW YORK (GenomeWeb News) – Bruker said today that it has entered an agreement with Loos, France-based biotech firm ImaBiotech to distribute that company's Quantinetix software for MALDI mass spec imaging.

NEW YORK (GenomeWeb News) – CovalX and Bruker's Daltonics division today announced an agreement to combine their technologies to support research into protein interactions and macromolecular characterization.

NEW YORK (GenomeWeb News) – Bruker said today it has signed an exclusive patent license agreement with 3M Company that allows it to include in its products patented 3M technology related to MALDI mass spec imaging.

NEW YORK (GenomeWeb News) – Bruker said today it has entered an exclusive partnership with German software firm Scils for informatics tools supporting MALDI mass spec imaging.

NEW YORK (GenomeWeb News) – BD Diagnostics and Bruker are updating a 2010 agreement to include international distribution of the co-labeled BD Bruker Maldi Biotyper system.

Bruker and the University of Victoria-Genome British Columbia Proteomics Centre said this week that they are collaborating on high-throughput iMALDI mass spec-based assays for determining genetic hemoglobin variants and diabetes risk.

Pages

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.